

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

RUBINSZTEIN et al.

Atty. Ref.: 620-394; Confirmation No. 1781

Appl. No. 10/553,262

TC/A.U. 1617

Filed: December 20, 2005

Examiner: Zarek

For: METHODS AND MEANS FOR TREATING PROTEIN CONFORMATIONAL
DISORDERS

* * * * *

May 22, 2009

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

RESPONSE

Responsive to the Official Action dated March 23, 2009, the applicants elect the subject matter of the Examiner's Group I for further prosecution in the above.

The applicants further elect, for the purpose of initial examination, Huntington's disease as a protein conformation disorder and rapamycin macrolides as an autophagy stimulating agent. Claims 41-43 and 45-51 read on the elected species.

The applicants believe the above is completely responsive to the Office Action of March 23, 2009 and an early and favorable Action on the merits of the claimed invention is requested.

The applicants note, for completeness, that rapamycin macrolides are all lactam macrolides and are therefore structurally closely related, as described in pages 5-8 of

RUBINSZTEIN et al.
Appl. No. 10/553,262
Atty. Ref.: 620-394
Response
May 22, 2009

the specification. The Examiner is requested therefore to examine rapamycin and its analogues as elected above.

An early and favorable Action is requested. The Examiner is requested to contact the undersigned, preferably by telephone, in the event anything further is required.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: /B. J. Sadoff/
 B. J. Sadoff
 Reg. No. 36,663

BJS:
901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100